Institutional investors purchased a net $230.2 thousand shares of RGEN during the quarter ended September 2015 and now own 92.10% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
CONESTOGA CAPITAL ADVISORS LLC Bought 201.9 Thousand shares of Repligen Corp
KALMAR INVESTMENTS, INC. Bought 81.6 Thousand shares of Repligen Corp
PRINCIPAL MANAGEMENT CORP. Bought 34.6 Thousand shares of Repligen Corp